Printer Friendly


 AMSTERDAM, May 11 /PRNewswire/ -- Affymax N.V. (NASDAQ: AFMXF) today announced that senior management for its wholly owned subsidiary Affymetrix would be David B. Singer, president and chief executive officer, and Stephen P.A. Fodor, Ph.D., scientific director and chief technical officer.
 Affymetrix is developing innovative DNA-based systems for research instrumentation and clinical diagnostics, as well as the emerging genetic analysis market based on Affymax's VLSIPS(TM) chip technology. This technology may enable researchers and clinicians to explore genetic information rapidly and cost-effectively. Scientists at Affymetrix received a $2.2 million NIH Human Genome Grant in October 1992 to support development of the VLSIPS technology for application to DNA sequencing.
 "Information generated by the Human Genome Project and advances in molecular genetics have led to a much better understanding of the molecular basis of disease," stated John D. Diekman, president of Affymax and chairman of the board of Affymetrix. "Affymetrix is an independent, entrepreneurial business unit poised to capture the instrumentation and diagnostic opportunities presented by these tremendous advances in molecular genetics."
 Affymetrix is assembling an independent board of directors which will include Alejandro C. Zaffaroni, chairman and chief executive officer of Affymax. The company currently has 30 employees and is located in Santa Clara, Calif.
 Singer is currently vice president of finance and treasurer of Affymax. He joined Affymax in 1990 as director, business development from Baxter Healthcare Corp. Singer holds a B.A. in history from Yale University and an MBA from Stanford Graduate School of Business.
 Fodor joined Affymax in 1989, most recently serving as vice president and director of physical sciences for Affymax Research Institute. He was the lead author on the initial VLSIPS paper and recently received the Distinguished Inventor Award from the Intellectual Property Owners' Association for this invention. Fodor received his Ph.D. in chemistry from Princeton University.
 Affymax is developing new technologies to accelerate the pace of drug discovery. Affymax is applying these technologies across a broad range of diseases to discover and develop products independently and in collaboration with established pharmaceutical companies. The majority of the company's research and development activities are performed by its wholly owned subsidiary, Affymax Research Institute, located in Palo Alto and Santa Clara. The company is pursuing opportunities in diagnostics through a wholly owned subsidiary, Affymetrix.
 -0- 5/11/93
 /CONTACT: Diana Kapp of Affymax, 415-496-2379/

CO: Affymax N.V.; Affymetrix ST: California IN: MTC SU: PER

SG-TM -- SJ001 -- 6857 05/11/93 08:33 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 11, 1993

Related Articles
Affymetrix Launches New Genome Scanning GeneChip(R) Expression Products.
Affymetrix Completes Reincorporation in Delaware.
Affymetrix Promotes Siegel to President.
Affymetrix Expands Management Team.
Affymetrix to Host Conference Call on April 21, 2004 to Announce First Quarter 2004 Results.
Affymetrix to Host Conference Call to Announce Fourth Quarter and Fiscal 2003 Results.
Affymetrix to Webcast Presentations at November Financial Conferences.
Affymetrix to Host Conference Call to Announce Third Quarter 2003 Results.
Affymetrix Launches Co-Marketing Partnership with Ingenuity Systems And Purchases Stake in Company; Ingenuity Pathways Analysis Application Expected...
Affymetrix Updates First Quarter.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters